| Literature DB >> 34531963 |
Milou L V Covers1, Ad de Jongh2,3,4,5, Rafaële J C Huntjens6, Carlijn de Roos7, Marcel van den Hout8, Iva A E Bicanic1.
Abstract
Background: About 40% of rape victims develop post-traumatic stress disorder (PTSD) within three months after the assault. Considering the high personal and societal impact of PTSD, there is an urgent need for early (i.e. within three months after the incident) interventions to reduce post-traumatic stress in victims of rape. Objective: To assess the effectiveness of early intervention with eye movement desensitization and reprocessing (EMDR) therapy to reduce symptoms of post-traumatic stress, feelings of guilt and shame, sexual dysfunction, and other psychological dysfunction (i.e. general psychopathology, anxiety, depression, and dissociative symptoms) in victims of rape. Method: This randomized controlled trial included 57 victims of rape, who were randomly allocated to either two sessions of EMDR therapy or treatment as usual ('watchful waiting') between 14 and 28 days post-rape. Psychological symptoms were assessed at pre-treatment, post-treatment, and 8 and 12 weeks post-rape. Linear mixed models and ANCOVAs were used to analyse differences between conditions over time.Entities:
Keywords: EMDR therapy; EMDR 疗法; PTSD; TEPT; Terapia EMDR; agresión sexual; early intervention; intervención temprana; rape; sexual assault; violación; 强奸; 性侵犯; 早期干预
Mesh:
Year: 2021 PMID: 34531963 PMCID: PMC8439210 DOI: 10.1080/20008198.2021.1943188
Source DB: PubMed Journal: Eur J Psychotraumatol ISSN: 2000-8066
Time of assessment and internal consistency per outcome measure
| Instrument | Total score range | Time of assessment | Internal consistency |
|---|---|---|---|
| Post-traumatic stress symptoms | |||
| Clinician Administered PTSD Scale (CAPS-5; Boeschoten et al., | 0–80 | Post, 8, 12 | .889 |
| PTSD Checklist for the DSM 5 (PCL-5; Weathers et al., | 0–80 | Pre, Post, 8, 12 | .940 |
| Psychological functioning | |||
| Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, | 0–21 | Pre, Post, 8, 12 | .859 |
| Hospital Anxiety and Depression Scale (HADS) Anxiety scale | 0–21 | Pre, Post, 8, 12 | .893 |
| Brief Symptom Inventory (BSI; De Beurs & Zitman, | 0–212 | Pre, 8, 12 | .972 |
| Dissociation Tension Scale (DTS; Stiglmayr et al., | 0–100 | Pre, Post, 8, 12 | .941 |
| Sexual functioning | |||
| Amsterdam Overactive Pelvic Floor Scale for Women (AOPFS; Van Lunsen & Van Laan, | 6–30 | Pre, 12 | .893 |
| Female Sexual Functioning Index (FSFI; Rosen et al., | 1.6–36 | Pre, 12 | .972 |
| Female Sexual Functioning Index (FSFI) Desire and Satisfaction | 1.6–12 | Pre, 12 | .797 |
| Item on sexual desire (based on Tarquinio, Brennstuhl, Reichenbach, Rydberg, & Tarquinio, | 1–5 | Pre, 12 | NA |
| Guilt/shame | |||
| Items on feelings of guilt and shame (based on Foa, Rothbaum, Riggs, & Murdock, | 1–5 | Pre, 12 | NA |
Time of assessment is defined as pre-treatment (Pre), post-treatment (Post), follow-up at eight weeks post-rape and follow-up at 12 weeks post-assault. Internal consistency is calculated with Cronbach’s alpha. For all measures higher scores indicate more psychopathology, with the exception of the FSFI, where higher scores indicate less psychopathology. The CAPS-5 was not administered at the pre-treatment assessment in order to facilitate study participation.
Figure 1.Attrition flow chart
Participant characteristics
| EMDR | TAU | |||
|---|---|---|---|---|
| % | % | |||
| Relationship to perpetrator (known) | 20/27 | 74% | 20/25 | 80% |
| Prior sexual assault experience | 5/18 | 28% | 6/14 | 43% |
| Prior trauma-based treatment | 6/19 | 32% | 2/14 | 14% |
| Conscious during recent rape | 14/17 | 82% | 9/13 | 69% |
Variables were missing for some participants. n refers to the ratio of observed to measured.
Mean and standard deviations of each outcome variable per assessment
| EMDR | TAU | ||||||
|---|---|---|---|---|---|---|---|
| Measure | Assessment | ||||||
| PCL-5 | Pre | 27 | 45.69 | 13.45 | 25 | 47.84 | 13.65 |
| Post | 22 | 32.10 | 16.89 | 20 | 37.95 | 11.26 | |
| 8 weeks | 19 | 24.49 | 18.53 | 19 | 32.57 | 18.31 | |
| 12 weeks | 20 | 22.09 | 16.41 | 17 | 23.29 | 17.94 | |
| CAPS-5 | Post | 22 | 28.95 | 14.60 | 19 | 33.05 | 10.63 |
| 8 weeks | 19 | 22.79 | 14.95 | 19 | 27.05 | 16.25 | |
| 12 weeks | 19 | 17.74 | 13.81 | 17 | 21.00 | 14.67 | |
| HADS Depression | Pre | 27 | 10.70 | 4.74 | 25 | 8.80 | 4.01 |
| Post | 21 | 8.48 | 4.06 | 20 | 8.95 | 3.76 | |
| 8 weeks | 19 | 7.63 | 4.70 | 19 | 7.00 | 4.43 | |
| 12 weeks | 19 | 6.68 | 4.83 | 17 | 6.06 | 4.87 | |
| HADS Anxiety | Pre | 27 | 13.00 | 4.71 | 25 | 11.92 | 4.34 |
| Post | 21 | 8.81 | 3.98 | 20 | 10.75 | 3.45 | |
| 8 weeks | 19 | 7.98 | 4.28 | 19 | 9.47 | 4.02 | |
| 12 weeks | 19 | 7.00 | 4.59 | 17 | 7.41 | 4.90 | |
| DTS | Pre | 27 | 30.03 | 23.26 | 25 | 25.53 | 19.39 |
| Post | 21 | 9.68 | 11.45 | 20 | 16.02 | 13.43 | |
| 8 weeks | 19 | 6.95 | 7.79 | 18 | 13.02 | 13.08 | |
| 12 weeks | 19 | 4.62 | 3.96 | 17 | 8.15 | 10.23 | |
| BSI | Pre | 27 | 88.26 | 44.35 | 25 | 89.06 | 39.08 |
| 8 weeks | 19 | 49.16 | 33.24 | 18 | 54.51 | 36.43 | |
| 12 weeks | 19 | 42.07 | 29.66 | 17 | 43.17 | 36.23 | |
| AOPFS | Pre | 27 | 11.35 | 4.61 | 24 | 11.61 | 3.21 |
| 12 weeks | 19 | 9.25 | 2.08 | 16 | 11.07 | 2.83 | |
| FSFI desire and satisfaction | Pre | 27 | 4.04 | 2.61 | 24 | 4.46 | 2.22 |
| 12 weeks | 19 | 5.46 | 3.05 | 16 | 5.91 | 2.55 | |
| Change in sexual desire | Pre | 27 | 2.00 | 1.49 | 25 | 2.32 | 1.49 |
| 12 weeks | 19 | 2.68 | 1.80 | 17 | 3.00 | 1.54 | |
| Guilt | Pre | 27 | 3.00 | 1.47 | 25 | 3.24 | 1.45 |
| 12 weeks | 19 | 1.42 | 0.84 | 17 | 1.94 | 0.97 | |
| Shame | Pre | 27 | 3.22 | 1.45 | 25 | 3.68 | 1.35 |
| 12 weeks | 19 | 1.74 | 0.81 | 17 | 2.59 | 1.28 | |
PCL-5 = PTSD Checklist for DSM-5; CAPS = Clinician Administered PTSD Scale for DSM-5; HADS = Hospital Anxiety and Depression Scale; DTS = Dissociation Tension Scale; BSI = Brief Symptom Inventory; AOPFS = Amsterdam Overactive Pelvic Floor Scale for Women; FSFI = Female Sexual Functioning Index.
Between-group effect sizes at posttreatment and follow-up assessments and within-group effect sizes in Cohen’s d
| Between-group effect size | Within-group effect size | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Post-treatment | 8 weeks | 12 weeks | Pre-treatment to post-treatment | Pre-treatment to 8 weeks | Pre-treatment to 12 weeks | ||||
| EMDR | TAU | EMDR | TAU | EMDR | TAU | ||||
| PCL-5 | 0.41 | 0.44 | 0.07 | 0.89 | 0.79 | 1.31 | 0.95 | 1.57 | 1.54 |
| CAPS-5 | 0.32 | 0.27 | 0.23 | - | - | - | - | - | - |
| HADS Depression | 0.12 | 0.14 | 0.13 | 0.50 | 0.04 | 0.65 | 0.42 | 0.84 | 0.61 |
| HADS Anxiety | 0.52 | 0.36 | 0.09 | 0.96 | 0.30 | 1.12 | 0.59 | 1.29 | 0.97 |
| DTS | 0.51 | 0.56 | 0.46 | 1.24 | 0.59 | 1.33 | 0.76 | 1.52 | 1.12 |
| BSI | - | 0.15 | 0.03 | - | - | 1.00 | 0.96 | 1.22 | 1.22 |
| AOPFS | - | - | 0.73 | - | - | - | - | 0.59 | 0.18 |
| FSFI desire and satisfaction | - | - | −0.16 | - | - | - | - | 0.50 | 0.61 |
| Sexual desire | - | - | −0.19 | - | - | - | - | 0.41 | 0.45 |
| Guilt | - | - | 0.57 | - | - | - | - | 1.32 | 1.05 |
| Shame | - | - | 0.79 | - | - | - | - | 1.26 | 0.83 |
Positive between-group effect sizes indicate that the EMDR condition scored lower than the control condition. PCL-5 = PTSD Checklist for DSM-5; CAPS = Clinician Administered PTSD Scale for DSM-5; HADS = Hospital Anxiety and Depression Scale; DTS = Dissociation Tension Scale; BSI = Brief Symptom Inventory; AOPFS = Amsterdam Overactive Pelvic Floor Scale for Women; FSFI = Female Sexual Functioning Index.
Figure 2.Mean scores for the EMDR and control conditions on self-reported (PCL-5) and clinician reported post-traumatic stress symptoms (CAPS-5), dissociative symptoms (DTS) and anxiety symptoms (HADS anxiety) at pre-treatment, post treatment, and eight and 12 week follow-ups
Estimate outcomes of mixed model analyses
| Intercept | Pre-treatment | Condition | Time | Condition-time interaction | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8 weeks | 12 weeks | 8 weeks | 12 weeks | ||||||||||||||||||
| Est | SE | 95% CI | Est | SE | 95% CI | Est | SE | 95% CI | Est | SE | 95% CI | Est | SE | 95% CI | Est | SE | 95% CI | Est | SE | 95% CI | |
| PCL-5 | 8.40 | 7.17 | −6.08, | 0.60** | 0.14 | 0.33, | −4.92 | 3.63 | −12.27, | −5.86* | 2.71 | −11.36, | −14.57** | 3.22 | −21.10, | 0.43 | 3.82 | −7.31, | 6.66 | 4.48 | −2.41, |
| CAPS-5 | 33.05** | 2.96 | 27.06, | - | - | - | −4.10 | 4.05 | −12.28, | −6.00* | 2.20 | −10.45, | −11.80** | 2.83 | −17.54, | 1.65 | 3.11 | −4.65, | 1.84 | 3.94 | −6.14, |
| HADS Depression | 2.72 | 1.48 | −0.27, | 0.66** | 0.14 | 0.39, | −1.63 | 1.07 | −3.80, | −2.07** | 0.72 | −3.53, | −2.33* | 0.97 | −4.29, | 1.23 | 1.02 | −0.84, | 0.54 | 1.35 | −2.19, |
| HADS Anxiety | 4.39** | 1.48 | 1.39, | 0.51** | 0.11 | 0.30, | −2.25* | 0.95 | −4.17, | −1.39* | 0.62 | −2.65, | −2.97** | 0.91 | −4.82, | 0.58 | 0.88 | −1.20, | 1.19 | 1.27 | −1.39, |
| BSI | −1.06 | 1.46 | −4.02, | 0.85** | 0.15 | 0.55, | −0.04 | 0.64 | −1.34, | - | - | - | −0.93* | 0.38 | −1.69, | - | - | - | 0.39 | 0.51 | −0.65, |
| DTS | 1.41* | 0.52 | 0.36, | 0.46** | 0.09 | 0.28, | −1.14* | 0.44 | −2.02, | −0.58* | 0.26 | −1.12, −0.05 | −1.17** | 0.32 | −1.80, | 0.13 | 0.37 | −0.62, | 0.39 | 0.44 | −0.50, |
The pre-treatment assessment of the measure was the covariate in the respective analyses. Reference categories are TAU condition and post-treatment assessment. Effects of BSI, and DTS are based on transformed data. BSI was not assessed at post-treatment, so the reference category is the 8 week follow-up. PCL-5 = PTSD Checklist for DSM-5; CAPS = Clinician Administered PTSD Scale for DSM-5; HADS = Hospital Anxiety and Depression Scale; DTS = Dissociation Tension Scale; BSI = Brief Symptom Inventory. *p < .05 **p < .01.
Estimate outcome of ANCOVA analyses
| Intercept | Pre-treatment | Condition | |||||||
|---|---|---|---|---|---|---|---|---|---|
| SE | 95% CI | SE | 95% CI | SE | 95% CI | ||||
| AOPFS | 2.48** | 0.66 | 1.14, 3.81 | 0.58** | 0.10 | 0.38, 0.77 | −0.19 | 0.20 | −0.59, 0.22 |
| FSFI desire and satisfaction | 2.99** | 0.91 | 1.13, 4.85 | 0.59** | 0.17 | 0.24, 0.93 | −0.30 | 0.84 | −2.01, 1.40 |
| Change in sexual desire | 1.86** | 0.56 | 0.73, 2.99 | 0.45 | 0.23 | −0.01, 0.91 | −0.27 | 0.54 | −1.37, 0.83 |
| Guilt | 0.65 | 0.33 | 0.00, 1.33 | 0.29** | 0.10 | 0.08, 0.50 | −0.25 | 0.29 | −0.84, 0.35 |
| Shame | 0.69 | 0.44 | −0.20, 1.57 | 0.36** | 0.13 | 0.10, 0.63 | −0.43 | 0.36 | −1.15, 0.29 |
The pre-treatment assessment of the measure was the covariate in the respective analyses. Reference category is TAU condition. Effects of AOPFS are based on transformed data. AOPFS = Amsterdam Overactive Pelvic Floor Scale for Women; FSFI = Female Sexual Functioning Index. *p < .05 **p < .01.